Atara Biotherapeutics Inc
ATRA
NASDAQ
Biotechnology
$8.09
USD
-0.42 (-4.94%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $85.42M
Volume 66.2K
Revenue
$6.19M
TTM
-96.7%
YoY
Gross Margin
91%
TTM
+12.5%
YoY
Net Income
$-16.69M
TTM
-388.0%
YoY
Operating Cash Flow
$-21.89M
TTM
+65.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 17.6 | 3.5 | 1.6 | 0.5 | 0.6 |
YoY Growth | -38.6% | -91.4% | -95.1% | -99.5% | -96.4% |
Cost of Revenue | 0.6 | 0.1 | 0.1 | 0.1 | 0.2 |
Gross Profit | 17.0 | 3.3 | 1.5 | 0.4 | 0.4 |
Selling, General & Administrative | 6.5 | 4.0 | 4.3 | 3.6 | 3.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 13.8 | 6.9 | 4.1 | 3.8 | 5.2 |
Operating Income | 3.2 | -3.6 | -2.6 | -3.4 | -4.7 |
EBITDA | 3.4 | -3.5 | -2.5 | -3.3 | -4.7 |
Other Income / Expense | 0.0 | 0.0 | -0.0 | 0.0 | 0.0 |
Total Other Income / Expense | -0.8 | -0.7 | -0.8 | -0.8 | -0.1 |
Income Before Income Taxes | 2.4 | -4.3 | -3.4 | -4.1 | -4.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | 2.4 | -4.3 | -3.4 | -4.1 | -4.8 |
Consolidated Net Income / Loss | 2.4 | -4.3 | -3.4 | -4.1 | -4.8 |
Net Income Attributable to Common Shareholders | 2.4 | -4.3 | -3.4 | -4.1 | -4.8 |
Basic EPS | $0.20 | -$0.32 | -$0.25 | -$0.29 | -$0.32 |
Diluted EPS | $0.19 | -$0.32 | -$0.24 | -$0.29 | -$0.32 |
Basic Shares Outstanding | 12.2M | 13.6M | 13.7M | 14.1M | 15.0M |
Diluted Shares Outstanding | 12.3M | 13.6M | 14.1M | 14.1M | 15.0M |